Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021
November 08 2021 - 7:03AM
Trading in Novo Nordisk shares by board members, executives and
associated persons on 5 November 2021
Bagsværd, Denmark, 8 November 2021 — This
document discloses the data of the transaction(s) made in Novo
Nordisk shares by the company’s board members, executives and their
associated persons in accordance with Article 19 of Regulation No.
596/2014 on market abuse.
The company’s board members, executives and their associated
persons have given Novo Nordisk power of attorney on their behalf
to publish trading in Novo Nordisk shares by the company’s board
members, executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
In line with the Principles for remuneration of executives in
Novo Nordisk A/S (Remuneration Principles) the Board of Directors
may when recruiting new executives who are not employed by Novo
Nordisk at the time of employment provide a recruitment package in
the form of cash payment or share incentive programme.
The reporting in the attached document reflects shares granted
to Mr. Ludovic Helfgott in relation to his employment as executive
in 2019.
Definitions and background information:
Publication
Publication shall take place no later than three working days
after the trading by board members, executives or their associated
persons. Publication is only required when the total amount of
transactions of a specific board member/executive or his/her
associated persons in any one calendar year has reached EUR 20,000
(calculated individually).
Who are board members, executives and associated
persons?
Board members and executives are members of the Board of
Directors and Executive Management, respectively, of Novo Nordisk
A/S. Associated persons are defined as the following persons
associated to a board member/executive: 1) spouse or cohabitant, 2)
children under the age of 18 years, 3) Other relatives defined as
brothers, sisters, parents, grandparents, children, grandchildren,
cousins etc. who have shared the same household with a board member
or executive for a period of at least one year on the date of the
given transaction and 4) any legal persons, trust, or partnership,
the managerial responsibilities of which are discharged by a board
member/executive or by a person referred to in items 1)-3) above,
or which is directly or indirectly controlled by such a person, or
which is set up for the benefit of such a person, or the economic
interests of which are substantially equivalent to those of such a
person.
What is trading/transaction?
Trading is any kind of transaction, including shares and share
related securities purchased or otherwise acquired, sold or
otherwise disposed, gifts, mortgages, heritage and grants,
allotments and exercise of options.
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq
Copenhagen and ADRs listed on New York Stock Exchange, except for
ADRs held in 401(k) retirement plan by US-based employees. The ID
code is the code (ISIN DK0060534915) of the Novo Nordisk share on
the Nasdaq Copenhagen or the code (NVO) on New York Stock
Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place
of transaction is the actual place of transaction, i.e. Nasdaq
Copenhagen or New York Stock Exchange.
What is the volume and price of transaction and aggregated
information?
The volume of transaction is the number of shares (of DKK 0.20
nominal value) or other financial instruments traded. In case of a
single transaction the price is the price of that single
transaction. In case of multiple transactions, when the
transactions relate to the same financial instrument, are of the
same nature, are executed on the same day and are executed on the
same place, the volume must be aggregated. The price of the
aggregated transactions is the weighted average price.
The exchange rate of the Danish Central Bank (Nationalbanken) on
the date of transaction is used for calculating the transaction
value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines, and working to prevent and ultimately cure disease. Novo
Nordisk employs about 47,000 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 4442
3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077
6915 |
dhel@novonordisk.com |
Mark Joseph
Root |
+45 3079
4211 |
mjhr@novonordisk.com |
Company announcement No 71 / 2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024